Skip to main content
Erschienen in: Journal of Neurology 9/2017

02.08.2017 | Original Communication

Early predictive factors of disability in CIDP

verfasst von: Emanuele Spina, Antonietta Topa, Rosa Iodice, Stefano Tozza, Lucia Ruggiero, Raffaele Dubbioso, Marcello Esposito, Dario Bruzzese, Lucio Santoro, Fiore Manganelli

Erschienen in: Journal of Neurology | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to identify early clinical, biochemical and electrophysiological prognostic factors of disability in CIDP. We evaluated a dataset from 60 CIDP patients that included sex, age of onset, type of onset, phenotype, disease duration, response to treatment, disability at the time of diagnosis assessed using the modified Rankin Scale (baseline mRS), cerebrospinal fluid protein levels and electrophysiological data. All patients had clinical assessment of disability through the mRS within the last 6 months (last mRS) before enrollment in the study. Stepwise forward logistic regression model was applied to evaluate the impact of clinical, biochemical and electrophysiological parameters on the last mRS, considered as binary outcome (absence or presence of severe disability, i.e., <4/≥4 mRS). Moreover, we used Spearman’s rank correlation coefficient to evaluate the relationship between disease duration and last mRS. We observed a significant relationship between last mRS and baseline mRS [p = 0.015, z = 2.44, OR 5.15 (CI 1.38–19.22)] and age of onset [p = 0.017, z = 2.39, OR 1.13 (CI 1.02–1.27) per additional year of age of onset]. There was no correlation between disease duration and last mRS. Our data suggest that a worse clinical status at the beginning of disease and an older age at onset may be negative prognostic factors of long-term disability independent from disease duration.
Literatur
1.
Zurück zum Zitat Nobile-Orazio E (2014) Chronic inflammatory demyelinating polyradiculoneuropathy and variant: where we are and where we should go. J Periph Nerv Syst 19(1):2–13CrossRef Nobile-Orazio E (2014) Chronic inflammatory demyelinating polyradiculoneuropathy and variant: where we are and where we should go. J Periph Nerv Syst 19(1):2–13CrossRef
2.
Zurück zum Zitat Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19(5):604–607CrossRefPubMed Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19(5):604–607CrossRefPubMed
3.
Zurück zum Zitat Cocito D, Paolasso I, Antonini G, Benedetti L, Briani C, Comi C, Fazio R, Jann R, Matà S, Mazzeo A, Sabatelli M (2010) Nobile-Orazio E, on behalf of the Italian Network of CIDP Register. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 17(2):289–294. doi:10.1111/j.1468-1331.2009.02802.x CrossRefPubMed Cocito D, Paolasso I, Antonini G, Benedetti L, Briani C, Comi C, Fazio R, Jann R, Matà S, Mazzeo A, Sabatelli M (2010) Nobile-Orazio E, on behalf of the Italian Network of CIDP Register. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 17(2):289–294. doi:10.​1111/​j.​1468-1331.​2009.​02802.​x CrossRefPubMed
4.
Zurück zum Zitat Gorson KC, Allam G, Ropper AH (1997) Chronich inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 48:321–328CrossRefPubMed Gorson KC, Allam G, Ropper AH (1997) Chronich inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 48:321–328CrossRefPubMed
5.
Zurück zum Zitat Tackenberg B, Lünemann JD, Steinbrecher A, Rothenfusser-Korber E, Sailer M, Brück W, Schock S, Zschenderlein R, Zipp F, Sommer N (2007) Classification and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology 68(19):1622–1629CrossRefPubMed Tackenberg B, Lünemann JD, Steinbrecher A, Rothenfusser-Korber E, Sailer M, Brück W, Schock S, Zschenderlein R, Zipp F, Sommer N (2007) Classification and treatment responses in chronic immune-mediated demyelinating polyneuropathy. Neurology 68(19):1622–1629CrossRefPubMed
6.
Zurück zum Zitat Querol L, Rojas-Garcia R, Casasnovas C, Sedano MJ, Muñoz-Blanco JL, Alberti MA, Paradas C, Sevilla T, Pardo J, Capablo JL, Sivera R, Guerrero A, Gutierrez-Rivas E, Illa I (2013) Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study. Muscle Nerve 48(6):870–876. doi:10.1002/mus.23843 CrossRefPubMed Querol L, Rojas-Garcia R, Casasnovas C, Sedano MJ, Muñoz-Blanco JL, Alberti MA, Paradas C, Sevilla T, Pardo J, Capablo JL, Sivera R, Guerrero A, Gutierrez-Rivas E, Illa I (2013) Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study. Muscle Nerve 48(6):870–876. doi:10.​1002/​mus.​23843 CrossRefPubMed
7.
Zurück zum Zitat Bouchard C, Lacroix C, Plantè V, Adams D, Chedru F, Guglielmi JM, Said G (1999) Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 52(3):498–503CrossRefPubMed Bouchard C, Lacroix C, Plantè V, Adams D, Chedru F, Guglielmi JM, Said G (1999) Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 52(3):498–503CrossRefPubMed
8.
Zurück zum Zitat Van Doorn PA, Vermeulen M, Brand A, Mulder PG, Busch HF (1991) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol 48(2):217–220CrossRefPubMed Van Doorn PA, Vermeulen M, Brand A, Mulder PG, Busch HF (1991) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol 48(2):217–220CrossRefPubMed
9.
Zurück zum Zitat Kuitwaard K, Hahn AF, Vermeulen M, Venance SL, van Doorn PA (2015) Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 86(12):1331–1336. doi:10.1136/jnnp-2014-309042 CrossRefPubMed Kuitwaard K, Hahn AF, Vermeulen M, Venance SL, van Doorn PA (2015) Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 86(12):1331–1336. doi:10.​1136/​jnnp-2014-309042 CrossRefPubMed
10.
Zurück zum Zitat Choudhary PP, Hughes RA (1995) Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. QJM 88(7):493–502PubMed Choudhary PP, Hughes RA (1995) Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. QJM 88(7):493–502PubMed
11.
Zurück zum Zitat Hahn AF, Bolton CF, Zochodne D, Feasby TE (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled cross-over study. Brain 119(Pt.4):1067–1077CrossRefPubMed Hahn AF, Bolton CF, Zochodne D, Feasby TE (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled cross-over study. Brain 119(Pt.4):1067–1077CrossRefPubMed
12.
Zurück zum Zitat Iijima M, Yamamoto M, Hirayama M, Tanaka F, Katsuno M, Mori K, Koike H, Hattori N, Arimura K, Nakagawa M (2005) Clinical ed electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology 64(8):1471–1475CrossRefPubMed Iijima M, Yamamoto M, Hirayama M, Tanaka F, Katsuno M, Mori K, Koike H, Hattori N, Arimura K, Nakagawa M (2005) Clinical ed electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology 64(8):1471–1475CrossRefPubMed
13.
Zurück zum Zitat Iijima M, Tomita M, Morozumi S, Kawagashira Y, Nakamura T, Koike H, Katsuno M, Hattori N, Tanaka F, Yamamoto M, Sobue G (2009) Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP. Neurology 73(17):1348–1352. doi:10.1212/WNL.0b013e3181bd1139 CrossRefPubMed Iijima M, Tomita M, Morozumi S, Kawagashira Y, Nakamura T, Koike H, Katsuno M, Hattori N, Tanaka F, Yamamoto M, Sobue G (2009) Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP. Neurology 73(17):1348–1352. doi:10.​1212/​WNL.​0b013e3181bd1139​ CrossRefPubMed
14.
Zurück zum Zitat Chiò A, Cocito D, Bottacchi E, Buffa C, Leone M, Plano F, Mutani R (2007) Calvo A, the PARCIDP. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 78(12):1349–1353CrossRefPubMedPubMedCentral Chiò A, Cocito D, Bottacchi E, Buffa C, Leone M, Plano F, Mutani R (2007) Calvo A, the PARCIDP. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 78(12):1349–1353CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Kuwabara S, Misawa S, Mori M, Tanura M, Kubata M, Hattori T (2006) Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry 77(1):66–70CrossRefPubMedPubMedCentral Kuwabara S, Misawa S, Mori M, Tanura M, Kubata M, Hattori T (2006) Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry 77(1):66–70CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Joint Task Force of the EFNS/PNS (2010) European Federation of Neurological Societes/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst. 15(1):1–9. doi:10.1111/j.1529-8027.2010-00245.x CrossRef Joint Task Force of the EFNS/PNS (2010) European Federation of Neurological Societes/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst. 15(1):1–9. doi:10.​1111/​j.​1529-8027.​2010-00245.​x CrossRef
17.
Zurück zum Zitat Mygland A, Monstad P, Vedeler C (2005) Onset and course of chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 31(5):589–593CrossRefPubMed Mygland A, Monstad P, Vedeler C (2005) Onset and course of chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 31(5):589–593CrossRefPubMed
18.
19.
Zurück zum Zitat Sghirlanzoni A, Solari A, Ciano C, Mariotti C, Fallica E, Pareyson D (2000) Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients. Neurol Sci 21(1):31–37CrossRefPubMed Sghirlanzoni A, Solari A, Ciano C, Mariotti C, Fallica E, Pareyson D (2000) Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients. Neurol Sci 21(1):31–37CrossRefPubMed
22.
Zurück zum Zitat Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126(Pt. 4):770–782CrossRefPubMed Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126(Pt. 4):770–782CrossRefPubMed
23.
Zurück zum Zitat Becker M, Latarche C, Roman E, Debouverie M, Malaplate-Armand C, Guillemin F (2015) No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients. BMC Neurol 13(15):79. doi:10.1186/s12883-015-0330-4 CrossRef Becker M, Latarche C, Roman E, Debouverie M, Malaplate-Armand C, Guillemin F (2015) No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients. BMC Neurol 13(15):79. doi:10.​1186/​s12883-015-0330-4 CrossRef
24.
Zurück zum Zitat Amato MP, Ponziani G (2000) A prospective study on the prognosis of multiple sclerosis. Neurol Sci 21(4 Suppl 2):S831–S838CrossRefPubMed Amato MP, Ponziani G (2000) A prospective study on the prognosis of multiple sclerosis. Neurol Sci 21(4 Suppl 2):S831–S838CrossRefPubMed
26.
Zurück zum Zitat Tedeholm H, Skoog B, Lisovskaja V, Runmarker B, Nrman O, Anderesn O (2015) The outcome spectrum of multiple sclerosis: disability, mortality and a cluster predictors from onset. J Neurol 262(5):1148–1163. doi:10.1007/s00415-015-7674-y CrossRefPubMed Tedeholm H, Skoog B, Lisovskaja V, Runmarker B, Nrman O, Anderesn O (2015) The outcome spectrum of multiple sclerosis: disability, mortality and a cluster predictors from onset. J Neurol 262(5):1148–1163. doi:10.​1007/​s00415-015-7674-y CrossRefPubMed
27.
Zurück zum Zitat Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN (2013) Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 12:CD001797. doi:10.1002/14651858.CD001797 Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN (2013) Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 12:CD001797. doi:10.​1002/​14651858.​CD001797
28.
Zurück zum Zitat Dyck PJ, Litchy WJ, Kratz KM, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O’Brien PC (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36(6):838–845CrossRefPubMed Dyck PJ, Litchy WJ, Kratz KM, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O’Brien PC (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36(6):838–845CrossRefPubMed
29.
Zurück zum Zitat Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van Doorn P, Dalakas M, Bojar M, Swan A, Inflammatory Neuropathy Cause and Treatment (INCAT) Group (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50(2):195–201CrossRefPubMed Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van Doorn P, Dalakas M, Bojar M, Swan A, Inflammatory Neuropathy Cause and Treatment (INCAT) Group (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50(2):195–201CrossRefPubMed
30.
Zurück zum Zitat Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56(1):36–39CrossRefPubMedPubMedCentral Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56(1):36–39CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Kuwabara S, Ogawara K, Misawa S, Mori M, Hattori T (2002) Distribution pattern of demyelinating correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 72(1):37–42CrossRefPubMedPubMedCentral Kuwabara S, Ogawara K, Misawa S, Mori M, Hattori T (2002) Distribution pattern of demyelinating correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 72(1):37–42CrossRefPubMedPubMedCentral
Metadaten
Titel
Early predictive factors of disability in CIDP
verfasst von
Emanuele Spina
Antonietta Topa
Rosa Iodice
Stefano Tozza
Lucia Ruggiero
Raffaele Dubbioso
Marcello Esposito
Dario Bruzzese
Lucio Santoro
Fiore Manganelli
Publikationsdatum
02.08.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 9/2017
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-017-8578-9

Weitere Artikel der Ausgabe 9/2017

Journal of Neurology 9/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.